Tracking Weight-Loss Doses with the GLP-1 Plotter
For weight-loss protocols on semaglutide (Wegovy, Ozempic), tirzepatide (Zepbound, Mounjaro), or retatrutide, the plasma level plotter answers questions a scale alone can't: when will I hit steady-state? Why did my appetite return last week? Should I escalate or hold? This guide covers practical weight-loss applications.
1) When You Should Use the Plotter for Weight Loss
- Plateau diagnosis. Weight stalled? The plotter shows whether you've actually hit steady-state at this dose, or if you're still ramping. The two situations call for different responses.
- Escalation timing. Standard titration says "step up at week 4." The plotter shows whether your plasma level has actually plateaued — sometimes it hasn't yet, and a 1–2 week hold makes the next step easier.
- Missed dose recovery. Skipped a week? Plot shows how far the curve dropped — useful for planning the catch-up.
- Protocol comparison. Compare weekly 1 mg vs daily 0.14 mg microdose — same total weekly mg, very different plasma curves and side-effect profiles.
2) Reading the Curve for Weight-Loss Phases
| Phase | Curve Shape | What to Expect |
|---|---|---|
| Loading (Wks 1-4) | Steep rise | Rapid appetite reduction; initial weight loss is often water |
| Titration steps | New steeper rise after each escalation | 1-2 weeks of renewed nausea per step |
| Steady-state | Saw-tooth plateau | Predictable appetite suppression; consistent fat loss |
| Plateau-with-tolerance | Plateau but appetite returning | Receptor desensitization — discuss next step with prescriber |
| Wash-out | Steep decline after stopping | Appetite returns within 1-2 weeks; expect rebound hunger |
Worked Scenario: Plateau Diagnosis
You're 12 weeks into semaglutide, on 1.0 mg weekly, lost 18 lbs in months 1-2 but only 2 lbs in month 3. Plot shows:
- Curve has fully plateaued — you ARE at steady-state at 1.0 mg
- Recent pattern: stable, no escalation phase
- Conclusion: Either escalate to 1.7 mg per protocol, OR your weight loss is plateauing for non-PK reasons (caloric intake creep, metabolic adaptation)
Discuss with your prescriber. The plot tells you which lever to consider first.
Worked Scenario: Comparing Tirzepatide vs Semaglutide
Plot 8 weeks of weekly tirzepatide 5 mg, then plot 8 weeks of weekly semaglutide 1 mg in a separate session. Compare:
- Tirzepatide reaches steady-state faster (shorter t½)
- Trough-to-peak ratio is wider on tirzepatide
- Semaglutide curve is smoother, more forgiving of dose timing
Different curves, different lived experience — useful when discussing switching options.
Tracking Weight Alongside
The plotter doesn't track weight — that's by design (medical scope). For weight tracking pair it with:
- A weekly weigh-in (same day, same time)
- Body-composition trends if you have a smart scale
- Waist-circumference monthly
Note your weigh-ins next to plot screenshots — pattern matching becomes easier with a few months of data.
Plot your weight-loss protocol
Free. Sign in to sync across devices.
Frequently Asked Questions
Can the GLP-1 plotter tell me if I've actually hit a weight-loss plateau?
Yes. The plotter shows whether your plasma curve has fully plateaued at your current dose or whether you're still ramping up. A scale stall during steady-state suggests caloric or metabolic factors; a stall before steady-state suggests you may need more time before escalating.
When should I escalate my GLP-1 dose vs hold?
Standard titration says step up at week 4, but the plotter shows whether your plasma level has actually plateaued. If the curve is still rising, a 1-2 week hold can let your body finish adapting before the next step, which often makes the escalation easier on side effects.
How do I use the plotter to recover from a missed GLP-1 dose?
Skip adding the missed dose and the plot will automatically show how far the curve dropped. This visual cue helps you and your prescriber decide whether to resume at the same dose, drop back a step, or add a half-dose to ease the rebuild back to steady-state.
What's the difference between tirzepatide and semaglutide on the plotter?
Tirzepatide reaches steady-state faster due to its shorter half-life and shows a wider trough-to-peak ratio. Semaglutide produces a smoother curve that's more forgiving of dose timing. Plotting 8 weeks of each side by side reveals lived-experience differences that clinical trial averages obscure.
Does the GLP-1 plotter track my actual weight?
No, by design. The plotter is scoped to plasma simulation, not weight tracking, since that crosses into medical territory. Pair it with weekly weigh-ins, smart-scale body composition trends, and monthly waist measurements; note weigh-ins next to plot screenshots for pattern matching over months.